Can dermatomyositis cause seizures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Dermatomyositis Cause Seizures?

Dermatomyositis can cause seizures, but this is a rare and life-threatening complication that occurs primarily in juvenile dermatomyositis (JDM) through central nervous system (CNS) vasculopathy, with a mortality rate approaching 67% when CNS involvement occurs.

Epidemiology and Risk Profile

  • CNS involvement with seizures occurs in approximately 1% of hospitalized JDM patients, making it an uncommon but critical complication 1
  • This complication typically manifests within the first 10 months of disease onset 1
  • The mortality rate for JDM patients with CNS involvement is 66.6%, making early recognition essential for survival 1
  • CNS complications are rarely reported in adult-onset dermatomyositis, though they can occur 2

Clinical Presentation and Associated Features

When seizures occur in dermatomyositis, they are typically accompanied by specific warning signs:

  • Active cutaneous vasculopathy is the most consistent associated finding 1
  • Severe proximal muscle weakness often coexists with neurological symptoms 1
  • Hyperferritinemia and thrombocytopenia are common laboratory abnormalities 1
  • Anti-NXP2 antibody positivity has been documented in affected patients 1

Pathophysiologic Mechanisms

The underlying pathology involves two distinct presentations:

  • Cerebral vasculitis affecting CNS blood vessels 1
  • Cerebral macrophage activation syndrome, a severe systemic inflammatory condition 1
  • The systemic vasculopathy characteristic of dermatomyositis can extend to CNS vessels, though this is under-recognized 2

Critical Management Considerations

Immediate aggressive immunosuppression is required when CNS involvement is suspected:

  • Intravenous methylprednisolone (IVMP) pulse therapy should be initiated urgently 1
  • Plasma exchange may be necessary as salvage therapy 1
  • Both patients who survived in the recent case series achieved complete neurological recovery with aggressive treatment 1
  • Delayed recognition and treatment significantly increases mortality risk 1

Important Clinical Pitfalls

  • CNS involvement is easily missed because it is not included in standard dermatomyositis complication screening protocols outlined in major guidelines 3, 4
  • The major guidelines focus on interstitial lung disease, cardiac involvement, and malignancy screening but do not specifically address CNS complications 3, 4
  • Seizures may be accompanied by pseudoseizures and psychiatric symptoms like depression, complicating diagnosis 2
  • Brainstem involvement can be rapidly fatal 2

Contrast with Standard Dermatomyositis Complications

While guidelines emphasize monitoring for interstitial lung disease (present in ~8% of patients), cardiac involvement, and malignancy 3, 4, CNS involvement represents a distinct and more immediately life-threatening complication that requires different management. The standard complications listed in comprehensive dermatomyositis reviews do not typically include seizures as a primary manifestation 5, 6, 7.

In clinical practice, any dermatomyositis patient—particularly children—presenting with new-onset seizures and active cutaneous vasculitis should be treated as a medical emergency requiring immediate aggressive immunosuppression, as this represents one of the few potentially reversible causes of mortality in this disease.

References

Guideline

Complications and Management of Dermatomyositis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Evaluation of Dermatomyositis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Dermatomyositis: An Update on Diagnosis and Treatment.

American journal of clinical dermatology, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.